FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068831761> ?p ?o ?g. }

• W2068831761 endingPage "4494" @default.
• W2068831761 startingPage "4494" @default.
• W2068831761 abstract "Abstract Purpose; PI3K (phosphatidylinositol-3-kinase) and its downstream mTOR (mammalian target of rapamycin) pathway play a critical role in diverse cellular functions, including proliferation, growth and cell survival. PI3K-mTOR pathway is frequently activated in endometrial cancer through various PI3K/AKT activating genetic alterations, such as mutations in PTEN, PIK3CA, and K-Ras. It has not been well analyzed whether mTOR inhibition alone is as effective as dual PI3K/mTOR inhibition to cancer cells with the activating PI3K pathway mutations, especially in vivo. In this study, we compared in vivo anti-tumor activity of a dual PI3K.inhibitor, NVP-BEZ235, with an mTOR inhibitor, RAD001, in endometrial cancer cell lines with the PI3K/AKT activating mutations.Experimental procedure; We screened 13 endometrial cancer cell lines, 11 of which possess one or more PI3K/AKT activating mutations. Among them, we selected two cell lines; AN3CA with a nonsense mutation in PTEN, and Hec-59 with double mutations in PIK3CA and PTEN. The IC50 values for cell proliferation by RAD001 were 14nM in AN3CA and 220nM in Hec-59, whereas the values by NVP-BEZ235 were 20nM in AN3CA and 24nM in Hec-59. We examined the effect of RAD001 (2.5mg/kg/day) and BEZ235 (40mg/kg/day) on tumor growth in vivo, using mice inoculated with endometrial cancer cells. We analyzed the phosphorylation levels of Akt, FOXO, GSK3beta and S6 in the tumors by immunoblotting. Results;Both BEZ and RAD001, compared with placebo, significantly suppressed the tumor growth in xenograft mice in the two cell lines. No significant adverse effects were observed with either compounds in any of the mice. Inconsistent with the in vitro data, the effect was comparable between BEZ235 and RAD001 even in Hec-59 cells, although the IC50 value was much higher with RAD001 than NVP-BEZ235. In Hec-59, NVP-BEZ235 clearly suppressed all the phosphorylation level of Akt, FOXO, GSK3beta and S6 in one hour from the treatment. However, all the phosphorylation levels were completely recovered to the base level within 24 hours. RAD001 clearly suppressed the p-S6 level in 1 hour and the effect partly remained even after 24 hours from the treatment. Conclusion; We demonstrated that both NVP-BEZ235 and RAD001 suppressed tumor growth in vivo in endometrial cancer cell lines with PIK3CA and/or PTEN mutations. The comparable effect of NVP-BEZ235 and RAD001 might be explained by the recovery of the phosphorylation levels of the target proteins, such as p-Akt, suggesting that sufficient suppression of the PI3K/mTOR pathway for full time-course might be required to robustly induce the anti-tumor effect by these inhibitors. In clinical trials, both pharmacokinetic and pharmacodinamic analyses would be important to appropriately assess the effect of these inhibitors. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4494. doi:10.1158/1538-7445.AM2011-4494" @default.
• W2068831761 created "2016-06-24" @default.
• W2068831761 creator A5003603090 @default.
• W2068831761 creator A5004301579 @default.
• W2068831761 creator A5010124046 @default.
• W2068831761 creator A5025762592 @default.
• W2068831761 creator A5028400668 @default.
• W2068831761 creator A5029989187 @default.
• W2068831761 creator A5036135855 @default.
• W2068831761 creator A5040448328 @default.
• W2068831761 creator A5070762738 @default.
• W2068831761 creator A5076130913 @default.
• W2068831761 creator A5091207706 @default.
• W2068831761 date "2011-04-01" @default.
• W2068831761 modified "2023-09-30" @default.
• W2068831761 title "Abstract 4494: In vivo antitumor activity of NVP-BEZ235, a dual PI3K/mTOR inhibitor, and RAD001 (everolimus), an mTOR inhibitor, in endometrial cancer" @default.
• W2068831761 doi "https://doi.org/10.1158/1538-7445.am2011-4494" @default.
• W2068831761 hasPublicationYear "2011" @default.
• W2068831761 type Work @default.
• W2068831761 sameAs 2068831761 @default.
• W2068831761 citedByCount "2" @default.
• W2068831761 countsByYear W20688317612019 @default.
• W2068831761 countsByYear W20688317612023 @default.
• W2068831761 crossrefType "journal-article" @default.
• W2068831761 hasAuthorship W2068831761A5003603090 @default.
• W2068831761 hasAuthorship W2068831761A5004301579 @default.
• W2068831761 hasAuthorship W2068831761A5010124046 @default.
• W2068831761 hasAuthorship W2068831761A5025762592 @default.
• W2068831761 hasAuthorship W2068831761A5028400668 @default.
• W2068831761 hasAuthorship W2068831761A5029989187 @default.
• W2068831761 hasAuthorship W2068831761A5036135855 @default.
• W2068831761 hasAuthorship W2068831761A5040448328 @default.
• W2068831761 hasAuthorship W2068831761A5070762738 @default.
• W2068831761 hasAuthorship W2068831761A5076130913 @default.
• W2068831761 hasAuthorship W2068831761A5091207706 @default.
• W2068831761 hasConcept C11960822 @default.
• W2068831761 hasConcept C121608353 @default.
• W2068831761 hasConcept C126322002 @default.
• W2068831761 hasConcept C134018914 @default.
• W2068831761 hasConcept C207001950 @default.
• W2068831761 hasConcept C2777088508 @default.
• W2068831761 hasConcept C2777609662 @default.
• W2068831761 hasConcept C2779699572 @default.
• W2068831761 hasConcept C43060935 @default.
• W2068831761 hasConcept C502942594 @default.
• W2068831761 hasConcept C54355233 @default.
• W2068831761 hasConcept C55493867 @default.
• W2068831761 hasConcept C62112901 @default.
• W2068831761 hasConcept C62478195 @default.
• W2068831761 hasConcept C71924100 @default.
• W2068831761 hasConcept C75217442 @default.
• W2068831761 hasConcept C86554907 @default.
• W2068831761 hasConcept C86803240 @default.
• W2068831761 hasConcept C95444343 @default.
• W2068831761 hasConceptScore W2068831761C11960822 @default.
• W2068831761 hasConceptScore W2068831761C121608353 @default.
• W2068831761 hasConceptScore W2068831761C126322002 @default.
• W2068831761 hasConceptScore W2068831761C134018914 @default.
• W2068831761 hasConceptScore W2068831761C207001950 @default.
• W2068831761 hasConceptScore W2068831761C2777088508 @default.
• W2068831761 hasConceptScore W2068831761C2777609662 @default.
• W2068831761 hasConceptScore W2068831761C2779699572 @default.
• W2068831761 hasConceptScore W2068831761C43060935 @default.
• W2068831761 hasConceptScore W2068831761C502942594 @default.
• W2068831761 hasConceptScore W2068831761C54355233 @default.
• W2068831761 hasConceptScore W2068831761C55493867 @default.
• W2068831761 hasConceptScore W2068831761C62112901 @default.
• W2068831761 hasConceptScore W2068831761C62478195 @default.
• W2068831761 hasConceptScore W2068831761C71924100 @default.
• W2068831761 hasConceptScore W2068831761C75217442 @default.
• W2068831761 hasConceptScore W2068831761C86554907 @default.
• W2068831761 hasConceptScore W2068831761C86803240 @default.
• W2068831761 hasConceptScore W2068831761C95444343 @default.
• W2068831761 hasIssue "8_Supplement" @default.
• W2068831761 hasLocation W20688317611 @default.
• W2068831761 hasOpenAccess W2068831761 @default.
• W2068831761 hasPrimaryLocation W20688317611 @default.
• W2068831761 hasRelatedWork W1599602125 @default.
• W2068831761 hasRelatedWork W1993312761 @default.
• W2068831761 hasRelatedWork W1998650136 @default.
• W2068831761 hasRelatedWork W2064116264 @default.
• W2068831761 hasRelatedWork W2227794049 @default.
• W2068831761 hasRelatedWork W2339548973 @default.
• W2068831761 hasRelatedWork W2991303558 @default.
• W2068831761 hasRelatedWork W3015650006 @default.
• W2068831761 hasRelatedWork W3139272788 @default.
• W2068831761 hasRelatedWork W3192317526 @default.
• W2068831761 hasVolume "71" @default.
• W2068831761 isParatext "false" @default.
• W2068831761 isRetracted "false" @default.
• W2068831761 magId "2068831761" @default.
• W2068831761 workType "article" @default.